Document is current
Any future updates will be listed below
-
Authors
Choi, Yejoo
Shin, Sungho
Son, Hyo Jin
Lee, Na-Hee
Myeong, Su Hyeon
Lee, Cheolju
Jang, Hyemin
Choi, Soo Jin
Kim, Hee Jin https://orcid.org/0000-0002-3186-9441
Na, Duk L.
-
Funding
Funding for this research was provided by:
Ministry of Science and ICT, South Korea (IITP-2022-2020-0-01821)
Ministry of Science and ICT, South Korea (HU21C0111)
Ministry of Science and ICT, South Korea (NRF 2022R1A2C2092346)
Ministry of Health and Welfare (HI14C3484)
Ministry of Health and Welfare (HX22C0027)
- License Information
-
More Information
Article History
Received: 1 July 2022
Accepted: 6 July 2023
First Online: 19 July 2023
Declarations
:
: This study was approved by Institutional Review Board of Samsung Medical Center and conformed to the Declaration of Helsinki. The project entitled ‘A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer’s Disease’ was approved by IRB (File No., 2013–09-076) on 9 December 2013; and the project entitled 'Identification of biomarkers to evaluate the effectiveness of stem cell treatment for Alzheimer's disease’ was approved by IRB (File No., 2017–04-025) on 20 June 2017. Informed consent was obtained from all the participants and their caregivers. This study was registered on Clinical Trials.gov, NCT02054208 on 4 February 2014.
: Not applicable.
: The authors declare they have no competing interests.
